Please login to the form below

Not currently logged in

Humira gets OK for childhood psoriasis in Europe

First biologic drug to be approved in the region for children as young as four

HumiraAbbVie's Humira has become the first biologic drug approved in Europe to treat plaque psoriasis in children as young as four.

Humira (adalimumab) - already one of the world's biggest-selling drugs with sales of $8.5bn last year - can now be used in the EU for children and adolescents with psoriasis who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies, as well as adults.

"Several treatments have been shown to be effective in subgroups of patients with paediatric psoriasis [but] a limited body of supporting data is available," said Marieke Seyger, a dermatologist at Radboud University Medical Centre in the Netherlands.

"The approval of adalimumab … extends the armamentarium of the physicians who are working to reduce the burden of this chronic disease in this sensitive young patient population," she added.

The tumour necrosis factor (TNF) blocker is currently licensed in the EU for the treatment of psoriasis, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis.

Humira has been a spectacular product for AbbVie but is facing increased competition in the anti-TNF drug class, with a biosimilar version of one of its main rivals - Janssen and MSD's Remicade (infliximab) - now on the market in around a dozen countries. 

Copies of Humira itself are expected on the market next year when patents on the drug expire in key markets, including the US. Meanwhile, in psoriasis, AbbVie's drug is expected to face stiff competition from newer biologics including interleukin-17 (IL-17) blockers from Novartis and AstraZeneca/Amgen.

AbbVie is attempting to maintain its lead over the competition by developing a new formulation of Humira that has already been submitted for approval in both the US and EU as well as new delivery devices that - at least for now - remain under wraps.

It is also working on additional indications - hidradenitis suppurativa (HS) and uveitis - that the company believes could add $1bn or more in sales to the franchise.

Article by
Phil Taylor

2nd April 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...